Sources and updates, November 12
Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
Read MoreSources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
Read MoreFollowing the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
Read MoreSources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
Read MoreThis week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.
Read MoreLast week, I asked you, COVID-19 Data Dispatch readers, to send me your stories of challenges you experienced when trying to get this fall’s COVID-19 vaccines. I received 35 responses from readers across the country, demonstrating issues with insurance coverage, pharmacy logistics, and more.
Read MoreEven though the updated COVID-19 vaccines are supposed to be free—either covered by insurance plans or by a federal program—people keep getting bills. I’d like to collect stories about vaccine access challenges here at the COVID-19 Data Dispatch.
Read MoreSources and updates for the week of September 17 include public comments to the CDC about infection controls, nasal spray recommendations, wastewater surveillance for flu, and more.
Read MoreWe now have two new COVID-19 vaccines available for this year’s respiratory virus season, one from Pfizer and one from Moderna, which are expected to perform well against current variants. The FDA approved both vaccines this week, and the CDC recommended them for almost all Americans. A third option, from Novavax, may become available in the coming weeks as well.
Read MoreI received a couple of reader questions in recent weeks that I’d like to answer here, in the hopes that my responses will be more broadly helpful. The questions cover COVID-19’s incubation period (i.e. time between exposure and symptoms), vaccine effectiveness for this fall, and nasal sprays.
Read MoreSources and updates for the week of August 20 include a wastewater data toolkit, vaccine delays, budget cuts at the CDC, and more.
Read More